The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2018 Aug 28

PMID 30147720

Citations 22

Authors

Aruchuna Ruban

Hutan Ashrafian

Julian P Teare

Affiliations

Soon will be listed here.

Abstract

The rapid rise of obesity and type 2 diabetes poses a global threat to healthcare and is a major cause of mortality and morbidity. Bariatric surgery has revolutionised the treatment of both these conditions but is invasive and associated with an increased risk of complications. The EndoBarrier is a device placed endoscopically in the duodenum, which is designed to mimic the effects of gastric bypass surgery with the aim of inducing weight loss and improving glycaemic control. This review outlines the current clinical evidence of the device, its efficacy, potential mechanisms of action, and utility in clinical practice.

Citing Articles

Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity.

Ghusn W, Calderon G, Abu Dayyeh B, Acosta A Clin Endosc. 2024; 57(6):701-710.

PMID: 39206501 PMC: 11637673. DOI: 10.5946/ce.2024.005.

The Saudi Gastroenterology Association consensus on the clinical care pathway for the diagnosis and treatment of GERD.

Alzahrani M, Alqaraawi A, Alzubide S, Abufarhaneh E, Alkhowaiter S, Alsulaimi M Saudi J Gastroenterol. 2024; 30(6):353-368.

PMID: 38813746 PMC: 11630483. DOI: 10.4103/sjg.sjg_82_24.

The synthesis and evaluation of thiolated alginate as the barrier to block nutrient absorption on small intestine for body-weight control.

Chen T, Tang R, Lin J, Kuo W, Yang I, Liang Y Bioeng Transl Med. 2023; 8(5):e10382.

PMID: 37693067 PMC: 10487312. DOI: 10.1002/btm2.10382.

Endobariatrics: a Still Underutilized Weight Loss Tool.

Dave N, Dawod E, Simmons O Curr Treat Options Gastroenterol. 2023; 21(2):172-184.

PMID: 37284352 PMC: 10163575. DOI: 10.1007/s11938-023-00420-6.

Updates in Endoscopic Bariatric and Metabolic Therapies.

Qureshi H, Saeed N, Jovani M J Clin Med. 2023; 12(3).

PMID: 36769774 PMC: 9917553. DOI: 10.3390/jcm12031126.

References

Jorgensen N, Jacobsen S, Dirksen C, Bojsen-Moller K, Naver L, Hvolris L . Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012; 303(1):E122-31. DOI: 10.1152/ajpendo.00073.2012. View

Koehestanie P, de Jonge C, Berends F, Janssen I, Bouvy N, Greve J . The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014; 260(6):984-92. DOI: 10.1097/SLA.0000000000000794. View

Furet J, Kong L, Tap J, Poitou C, Basdevant A, Bouillot J . Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010; 59(12):3049-57. PMC: 2992765. DOI: 10.2337/db10-0253. View

Koehestanie P, Dogan K, Berends F, Janssen I, Wahab P, Groenen M . Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open. 2015; 2(1):E21-7. PMC: 4423279. DOI: 10.1055/s-0034-1365222. View

Schouten R, Rijs C, Bouvy N, Hameeteman W, Koek G, Janssen I . A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2009; 251(2):236-43. DOI: 10.1097/SLA.0b013e3181bdfbff. View

Vrieze A, van Nood E, Holleman F, Salojarvi J, Kootte R, Bartelsman J . Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143(4):913-6.e7. DOI: 10.1053/j.gastro.2012.06.031. View

Cohen R, Shikora S, Petry T, Caravatto P, le Roux C . The Diabetes Surgery Summit II Guidelines: a Disease-Based Clinical Recommendation. Obes Surg. 2016; 26(8):1989-91. DOI: 10.1007/s11695-016-2237-6. View

Rodriguez-Grunert L, Galvao Neto M, Alamo M, Cardoso Ramos A, Baez P, Tarnoff M . First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008; 4(1):55-9. DOI: 10.1016/j.soard.2007.07.012. View

Kim W, Egan J . The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60(4):470-512. PMC: 2696340. DOI: 10.1124/pr.108.000604. View

10.

Patel N, Mohanaruban A, Ashrafian H, Le Roux C, Byrne J, Mason J . EndoBarrier®: a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?. Obes Surg. 2018; 28(7):1980-1989. PMC: 6018591. DOI: 10.1007/s11695-018-3123-1. View

11.

Gersin K, Rothstein R, Rosenthal R, Stefanidis D, Deal S, Kuwada T . Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010; 71(6):976-82. DOI: 10.1016/j.gie.2009.11.051. View

12.

Ashrafian H, Athanasiou T, Li J, Bueter M, Ahmed K, Nagpal K . Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev. 2010; 12(5):e257-72. DOI: 10.1111/j.1467-789X.2010.00802.x. View

13.

Penney N, Kinross J, Newton R, Purkayastha S . The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes (Lond). 2015; 39(11):1565-74. DOI: 10.1038/ijo.2015.115. View

14.

Betzel B, Homan J, Aarts E, Janssen I, de Boer H, Wahab P . Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc. 2016; 31(7):2881-2891. DOI: 10.1007/s00464-016-5299-6. View

15.

Ley R, Turnbaugh P, Klein S, Gordon J . Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444(7122):1022-3. DOI: 10.1038/4441022a. View

16.

Quezada N, Munoz R, Morelli C, Turiel D, Hernandez J, Pimentel F . Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years. Surg Endosc. 2017; 32(1):260-267. DOI: 10.1007/s00464-017-5672-0. View

17.

Jirapinyo P, Haas A, Thompson C . Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes. Diabetes Care. 2018; 41(5):1106-1115. DOI: 10.2337/dc17-1985. View

18.

de Moura E, Lopes G, Martins B, Orso I, Coutinho A, de Oliveira S . Effects of Duodenal-Jejunal Bypass Liner (EndoBarrier®) on Gastric Emptying in Obese and Type 2 Diabetic Patients. Obes Surg. 2015; 25(9):1618-25. DOI: 10.1007/s11695-015-1594-x. View

19.

Riedel N, Laubner K, Lautenbach A, Schon G, Schlensak M, Stengel R . Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner. Surg Obes Relat Dis. 2018; 14(6):769-779. DOI: 10.1016/j.soard.2018.02.029. View

20.

Whitson B, Leslie D, Kellogg T, Maddaus M, Buchwald H, Billington C . Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res. 2007; 141(1):31-9. DOI: 10.1016/j.jss.2007.02.022. View